Report on a WHO Consultation on the characterisation of BCG strains, Imperial College, London 15–16 December 2003

The potential benefits of a consultation on improved characterisation could include: improved vaccine characterisation: molecular genetic studies could be used to differentiate sub-strains used by different manufacturers; it may help to ensure consistency of production in terms of genetic stability;...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2004-07, Vol.22 (21), p.2675-2680
Main Authors: Corbel, M.J, Fruth, U, Griffiths, E, Knezevic, Ivana
Format: Article
Language:English
Subjects:
BCG Vaccine - adverse effects
BCG Vaccine - genetics
BCG Vaccine - immunology
Clinical trials
Evolution & development
Feasibility studies
Genomes
Humans
Laboratories
Meetings
Mycobacterium bovis - genetics
Mycobacterium bovis - immunology
Quality Control
Quality standards
Reverse Transcriptase Polymerase Chain Reaction
Tuberculosis
Vaccination - trends
Vaccines
World Health Organization
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The potential benefits of a consultation on improved characterisation could include: improved vaccine characterisation: molecular genetic studies could be used to differentiate sub-strains used by different manufacturers; it may help to ensure consistency of production in terms of genetic stability; and this may help in the future clinical evaluation of BCG vaccines. The objectives of the present meeting were: to provide scientific advice for future characterisation of BCG strains for vaccine production; a consensus on the need for further characterisation of strains for BCG vaccine production; to determine the need for a collaborative study on methodology; if needed, to identify the questions to be answered by the study; and to progress towards a consultation on the production and control of BCG vaccines. Examination of historical records showed that the Birkhaug, Brazil, Japan, Sweden and Russia sub-strains emerged soon after distribution of cultures derived from the 1921 parent strain.\n The final phase of the meeting was a discussion of the information presented and the future course of action.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2004.01.050